# Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease

> **NCT05771428** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 263 (actual)

## Conditions studied

- Alzheimer's Disease (AD)

## Interventions

- **DRUG:** ABBV-552
- **DRUG:** Placebo for ABBV-552

## Key facts

- **NCT ID:** NCT05771428
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-05
- **Primary completion:** 2024-08-06
- **Final completion:** 2024-09-12
- **Target enrollment:** 263 (ACTUAL)
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05771428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05771428, "Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05771428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*